君實生物(01877.HK):特瑞普利單抗注射液新增適應症納入國家醫保目錄
格隆匯12月3日丨君實生物(01877.HK)發佈公吿,近日,公司產品特瑞普利單抗注射液(商品名:拓益,產品代號:JS001)通過國家醫保談判,繼續納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2021版)》乙類範圍,並新增用於既往接受過二線及以上系統治療失敗的復發/轉移性鼻咽癌患者的治療、用於含鉑化療失敗包括新輔助或輔助化療12個月內進展的局部晚期或轉移性尿路上皮癌的治療兩個適應症範圍,特瑞普利單抗是國家醫保目錄中唯一用於黑色素瘤和鼻咽癌治療的抗PD-1單抗藥物。
本次特瑞普利單抗注射液新增適應症納入國家醫保目錄體現了國家醫療保障局對該藥物的臨牀價值、患者獲益、創新程度等方面的認可,填補了國家醫保目錄內晚期鼻咽癌及晚期尿路上皮癌非選擇性人羣免疫治療的空白。本次醫保談判的結果積極鼓勵了本土創新藥企的藥物研發和產業化工作,有助於公司進一步提高該藥物在患者中的可負擔性和可及性,有利於進一步推動該藥物的市場推廣、提升銷售規模,對公司的長期經營發展具有積極影響,預計短期內不會對經營業績產生重大影響。公司將緊密配合推進醫保政策落地,加速推進特瑞普利單抗注射液進入各醫院渠道,並持續與多方共同探索創新支付方式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.